Navigation Links
NovaBay Pharmaceuticals Announces Lead Anti-infective Product Candidate, NVC-422, Shown to be Effective in Treating Topical Fungal Infection
Date:3/7/2009

upport for continuing to develop NVC-422 for fungal infections."

NVC-422 is the most advanced of a series of compounds from a new class of drugs that mimics the body's natural defense against infection. NVC-422 may deliver the same or better efficacy as currently used antibiotics without contributing to the growing rise of bacterial resistance. The Company plans to file an exploratory Investigational New Drug application with the U.S. Food and Drug Administration in the second quarter of 2009 and initiate a Phase II clinical trial of NVC-422 during the second half of 2009 for impetigo, one of the most common skin infections among children, which produces blisters or sores on the face, neck, hands and diaper area.

"The ability to treat infection with a non-antibiotic is more important than ever because of the rise of drug resistant bacteria," said Dr. Ron Najafi, chairman and chief executive officer of NovaBay. "In developing anti-infective compounds, experience shows that preclinical results are more predictive of clinical efficacy than in other therapeutic categories, and I am encouraged that our preclinical work to date strongly suggests that NVC-422 may be a potent and well-tolerated treatment for numerous serious skin infections such as acne, nail fungus and topical viral infections, where antibiotics are not effective. Advancing NVC-422 into Phase II clinical trials reinforces the strength of our extensive preclinical work and, significantly, redefines NovaBay as a mid-stage biotech company."

NovaBay's experienced researchers have created a pipeline and research and development engine of first-in-class, broad-spectrum anti-bacterial and anti-fungal agents with low to no microbial resistance. In-vitro studies to date have shown that NVC-422 has a potentially expansive therapeutic utility against bacteria of all types, including multidrug resistant species; shedding viruses including adenoviruses; and
'/>"/>

SOURCE NovaBay Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Access Pharmaceuticals Announces Positive ProLindac(TM) Phase 2 Ovarian Cancer Clinical Trial Results
2. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
3. Adlyfe Strikes Translational Medicine Partnership With Wyeth Pharmaceuticals for Alzheimers Biomarker Assay
4. MAP Pharmaceuticals Announces Phase 3 Study of Unit Dose Budesonide in Children With Asthma Did Not Meet Primary Endpoints
5. AstraZenecas Partner, MAP Pharmaceuticals, Announces Phase 3 Study of Unit Dose Budesonide in Children with Asthma Did Not Meet Primary Endpoints
6. Shareholder Class Action Filed Against Rigel Pharmaceuticals, Inc. by the Law Firm of Barroway Topaz Kessler Meltzer & Check, LLP
7. Access Licenses ProLindac(TM) and MuGard(TM) to JCOM Ltd, an Affiliate of DONG-A Pharmaceuticals in Korea
8. Inspiration Biopharmaceuticals, Inc. Initiates Phase 1 Clinical Trial of IB1001 for the Treatment of Hemophilia B
9. Endo Pharmaceuticals Announces Research Collaborations to Develop Novel Pain Treatments and Discover Potential Cancer Treatments
10. Sequoia Pharmaceuticals Presents Proof of Clinical Concept of SPI-452, a Novel Pharmacokinetic Enhancer
11. Indevus Pharmaceuticals Announces PRO 2000 Found to Show Promise in Large HIV Prevention Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Tianyin Pharmaceutical Inc. (NYSE Amex: TPI ... patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded ... preliminary financial results for the first quarter of ... Ended September 30, 2014 Financial Highlights: , ... in 1Q14 with gross margins improved to 52% ...
(Date:12/24/2014)... , Dec. 24, 2014  Conkwest, Inc., the ... the proprietary Natural Killer (NK) cell-line platform, Neukoplast® ... Patrick Soon-Shiong , NantWorks founder, physician scientist ... agreement to purchase approximately $48 million of the ... the investment, he will be named Co-Chairman of ...
(Date:12/24/2014)... 23, 2014 PuraMed BioScience®, Inc., (OTC Pink: ... medicinal and healthcare products, announced it received the initial ... hemp-based, advanced headache relief product, for planned distribution to ... Colorado , Washington State , ... the MigraPure H Advanced headache relief gel formulation completed, ...
Breaking Medicine Technology:TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 2TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 3TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 4TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 5TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 6TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 7TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 8TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 9TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 10TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 11TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 12Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 2Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 3Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 4Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 5PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 2PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 3
... NEW YORK, Feb. 9, 2011 Reportlinker.com announces ... in its catalogue: European Markets ... http://www.reportlinker.com/p0377966/European-Markets-for-Spinal-Implants-and-VCF-2011.html iData,s comprehensive ... report is the industry leading research report for ...
... 2011 Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL ... chairman and chief executive officer, is scheduled to participate ... week. Details of the events are as follows:Tuesday, February ... Investor ConferencePanel Topic:  "Rheumatoid Arthritis: the Real Joint Problem"Tuesday, ...
Cached Medicine Technology:Reportlinker Adds European Markets for Spinal Implants and VCF 2011 2Rigel Announces Participation at Two Investor Conferences 2
(Date:12/24/2014)... News) -- Adults who experienced childhood abuse or ... suggests a study published online Dec. 24 in ... can have long-lasting effects, like associated medical and ... Dawn Buse, director of behavioral medicine at Montefiore ... a journal news release. "When managing patients ...
(Date:12/24/2014)... Tara Haelle HealthDay Reporter ... Teens are more likely to start smoking or drinking ... disorder (ADHD) or conduct disorder, new research suggests. ... about the risk of substance use as [these] children ... director at Cincinnati Pediatric Research Group, which is part ...
(Date:12/24/2014)... HealthDay Reporter TUESDAY, Dec. 23, 2014 ... (ADA) call for giving the cholesterol-lowering drugs known as statins ... These new standards bring the association in line with ... also recommend giving low- or high-dose statins to all people ... "We agree that the decision to start a statin should ...
(Date:12/24/2014)... 2014 For chic ladies, new fashionable outfits ... part of their Holiday Wish List, Angeldress.co.uk has ... ways to accent ladies’ holiday wardrobe by launching a promotion ... all over the discount of 80% off, like a cheap ... ship. The company’s chic wedding dresses are among the hottest ...
(Date:12/24/2014)... December 24, 2014 Dr. Svetlana Gomer, ... across the nation gathered with US Marines on November ... raise funds for the Toys for Tots Literacy Program. ... thousands of new books and audio books for the ... underprivileged children this Christmas. It represents another major strike ...
Breaking Medicine News(10 mins):Health News:Abuse in Childhood Tied to Migraines in Adulthood 2Health News:ADHD May Raise Teens' Odds for Smoking, Drinking 2Health News:ADHD May Raise Teens' Odds for Smoking, Drinking 3Health News:Nearly All Diabetics Should Be on Cholesterol-Lowering Drugs: Experts 2Health News:Nearly All Diabetics Should Be on Cholesterol-Lowering Drugs: Experts 3Health News:Angeldress.co.uk Starts Its Big Sales by Offering Various Kinds of Cheap Clothes and Fashion Accessories 2Health News:Dr. Svetlana Gomer, MGS Tewksbury Dental and Other Dentists Working With the U.S. Marines Strike Again In the Battle Against Illiteracy 2Health News:Dr. Svetlana Gomer, MGS Tewksbury Dental and Other Dentists Working With the U.S. Marines Strike Again In the Battle Against Illiteracy 3
... Anaemia, a killer horse disease, is not about to deter ... no bones that the show will go on// , despite ... ,Nine horses have been fatally hit by EIA, ... positive for the disease. Show director Gerry McAuliffe confirmed that ...
... years, 50 million American women will be in menopause. ... use of synthetic hormone replacement// therapy (HRT) in a ... left many women and physicians uncertain about the safety ... (“natural”) hormone replacement therapy (nBHRT) has been proposed by ...
... of them women, were taken ill after inhaling fumes ... Bolangir district// , official said Thursday. ,The agricultural ... a field at Khairmal village, some 15 km from ... medical officer Sarada Prasad Mishra told IANS on phone. ...
... new study in patients with type 2 diabetes demonstrate ... chromium picolinate// , in combination with a common oral ... than the oral anti-diabetic agent alone. ,The ... (PBRC) and the University of Vermont College of Medicine, ...
... The tragic drug trial that left six volunteers seriously ill ... University researchers are collaborating with scientists from the drugs firm ... patients are exposed to a tiny amount of the drug ... in the earlier drug trial. , ,"We can monitor ...
... Economy has shown that in utero health has a great ... study is important because of its ramifications on health programs ... that can have far reaching impact in adulthood, much more ... purposes is that whereas heredity is immutable, congenital characteristics are ...
Cached Medicine News:Health News:Bio-Identical Hormone Replacement Therapy 2Health News:Bio-Identical Hormone Replacement Therapy 3Health News:Supplementation with Chromium Picolinate Improves Glycemic Control 2Health News:Personal Growth and Success Dependent on Prenatal Health 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: